Advanced Renal Cell Carcinoma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeuti

AI Briefing

• – Advanced Renal Cell Carcinoma pipeline is extensive, with 50+ companies working on 60+ therapies.
• – DelveInsight assesses MOA, ROA, FDA-approved drugs, and clinical trial progress.
• – Key players include Molecure S.A., Daiichi Sankyo, and Janux Therapeutics, with ongoing trials and developments.